A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung Cancer

Trial Profile

A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Camptothecin (Primary) ; Olaparib (Primary)
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Planned number of patients changed from 75 to 138.
    • 04 Aug 2016 According to a Cerulean Pharma media release, first patient has been dosed in this trial second quarter 2016.
    • 10 May 2016 Top-line data from this trial is expected in the first half of 2017, according to a Cerulean Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top